MA49952B1 - Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations - Google Patents
Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisationsInfo
- Publication number
- MA49952B1 MA49952B1 MA49952A MA49952A MA49952B1 MA 49952 B1 MA49952 B1 MA 49952B1 MA 49952 A MA49952 A MA 49952A MA 49952 A MA49952 A MA 49952A MA 49952 B1 MA49952 B1 MA 49952B1
- Authority
- MA
- Morocco
- Prior art keywords
- oxoisoindolin
- piperidine
- dione derivatives
- ikzf2
- ikzf4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (i) : ou un sel, un hydrate, un solvate, un promédicament, un stéréoisomère ou un tautomère pharmaceutiquement acceptable de celui-ci, dans laquelle r1,r2, rx, xi, n, nl, et q sont tels que définis dans la description, des procédés de fabrication et d'utilisation pour le traitement de maladies ou de troubles dépendant de la famille à doigt de zinc 2 (ikzf2) ikaros ou dans lesquels la réduction des taux de protéines ikzf2 ou ikzf4 peut améliorer une maladie ou un trouble.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762549225P | 2017-08-23 | 2017-08-23 | |
PCT/IB2018/056400 WO2019038717A1 (fr) | 2017-08-23 | 2018-08-23 | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
MA49952A MA49952A (fr) | 2021-04-28 |
MA49952B1 true MA49952B1 (fr) | 2023-03-31 |
Family
ID=63638171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49952A MA49952B1 (fr) | 2017-08-23 | 2018-08-23 | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations |
Country Status (37)
Country | Link |
---|---|
US (5) | US10414755B2 (fr) |
EP (2) | EP3672949B9 (fr) |
JP (1) | JP7386787B2 (fr) |
KR (1) | KR20200044038A (fr) |
CN (1) | CN111051298B (fr) |
AR (1) | AR112529A1 (fr) |
AU (3) | AU2018319577B2 (fr) |
BR (1) | BR112020003373B1 (fr) |
CA (1) | CA3072694A1 (fr) |
CL (1) | CL2020000427A1 (fr) |
CO (1) | CO2020001860A2 (fr) |
CR (1) | CR20200081A (fr) |
CU (1) | CU20200014A7 (fr) |
DK (1) | DK3672949T5 (fr) |
DO (1) | DOP2020000037A (fr) |
EA (1) | EA202090553A1 (fr) |
EC (1) | ECSP20013248A (fr) |
ES (1) | ES2940448T3 (fr) |
FI (1) | FI3672949T3 (fr) |
HR (1) | HRP20230244T1 (fr) |
HU (1) | HUE061895T2 (fr) |
IL (1) | IL272748B2 (fr) |
JO (1) | JOP20200042A1 (fr) |
LT (1) | LT3672949T (fr) |
MA (1) | MA49952B1 (fr) |
MX (1) | MX2020002060A (fr) |
PH (1) | PH12020500125A1 (fr) |
PL (1) | PL3672949T3 (fr) |
PT (1) | PT3672949T (fr) |
RS (1) | RS64058B9 (fr) |
SA (1) | SA520411325B1 (fr) |
SG (1) | SG11202000490PA (fr) |
SI (1) | SI3672949T1 (fr) |
TW (1) | TWI793151B (fr) |
UY (1) | UY37854A (fr) |
WO (1) | WO2019038717A1 (fr) |
ZA (1) | ZA202000208B (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109562107A (zh) * | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
IL310860A (en) * | 2018-04-13 | 2024-04-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
US11192877B2 (en) | 2018-07-10 | 2021-12-07 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP3897637A1 (fr) * | 2018-12-20 | 2021-10-27 | Novartis AG | Schéma posologique et combinaison pharmaceutique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione |
US20220144807A1 (en) * | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP3924055B1 (fr) * | 2019-02-15 | 2024-04-03 | Novartis AG | Dérivés de 3-(1-oxoisoindoline-2-yl)pipéridine-2,6-dione substitués et leurs utilisations |
SG11202109024YA (en) * | 2019-04-12 | 2021-09-29 | C4 Therapeutics Inc | Tricyclic degraders of ikaros and aiolos |
EP3959320A1 (fr) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions et procédés de dégradation sélective de protéines |
KR20220030222A (ko) | 2019-05-31 | 2022-03-10 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
CN114650868A (zh) * | 2019-10-30 | 2022-06-21 | 达纳-法伯癌症研究公司 | Helios的小分子降解剂及其使用方法 |
CN110862395B (zh) * | 2019-11-13 | 2020-09-29 | 株洲千金药业股份有限公司 | 一种制备他达拉非重要杂质的原料化合物的制备方法 |
JP2023503052A (ja) * | 2019-11-19 | 2023-01-26 | ブリストル-マイヤーズ スクイブ カンパニー | Heliosタンパク質の阻害剤として有用な化合物 |
TW202140441A (zh) * | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
US20230203022A1 (en) * | 2020-04-30 | 2023-06-29 | Shanghaitech University | Heterocycle and glutarimide skeleton-based compound and applications thereof |
AU2021297099A1 (en) | 2020-06-23 | 2023-01-05 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US20230357193A1 (en) * | 2020-07-09 | 2023-11-09 | Sichuan Haisco Pharmaceutical Co., Ltd. | Compound capable of inhibiting and degrading androgen receptors, and pharmaceutical compositions and pharmaceutical uses thereof |
WO2022029573A1 (fr) * | 2020-08-03 | 2022-02-10 | Novartis Ag | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations |
CN116583509A (zh) * | 2020-10-07 | 2023-08-11 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
CR20230143A (es) * | 2020-10-16 | 2023-07-28 | Neomorph Inc | Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso |
WO2022120355A1 (fr) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Agents de dégradation de tead et leurs utilisations |
UY39671A (es) * | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
WO2022216644A1 (fr) | 2021-04-06 | 2022-10-13 | Bristol-Myers Squibb Company | Composés oxoisoindoline substitués par pyridinyle |
CN117355299A (zh) * | 2021-04-29 | 2024-01-05 | 尼奥莫夫公司 | 取代的2-(2,6-二氧代哌啶-3-基)-5-(1-哌啶-4-基)异吲哚啉-1,3-二酮衍生物及其用途 |
TW202317546A (zh) | 2021-07-09 | 2023-05-01 | 美商普萊克斯姆公司 | 調節ikzf2之芳基化合物及醫藥組合物 |
AU2022324621A1 (en) | 2021-08-06 | 2024-01-18 | Celgene Corporation | Compositions and methods for selective degradation of engineered proteins |
TW202321219A (zh) * | 2021-08-11 | 2023-06-01 | 大陸商四川海思科製藥有限公司 | 雜環衍生物及其組合物和藥學上的應用 |
CA3234909A1 (fr) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Derives de pyridine-3(2h)-one |
WO2023077030A1 (fr) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Composés cd73 |
WO2023122581A2 (fr) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées |
CA3237577A1 (fr) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Agents de degradation des doigts de zinc de la famille ikaros et leurs utilisations |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
CN116640122A (zh) * | 2022-02-16 | 2023-08-25 | 苏州国匡医药科技有限公司 | Ikzf2降解剂及包含其的药物组合物和用途 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
TW202345797A (zh) * | 2022-03-25 | 2023-12-01 | 美商昂科皮治療公司亦以普羅提歐凡治療公司名稱營業 | 作為ikzf2降解劑之含雙環雜芳基化合物 |
TW202341988A (zh) * | 2022-03-25 | 2023-11-01 | 密西根大學董事會 | Ikzf2降解劑及其用途 |
WO2023201012A1 (fr) * | 2022-04-15 | 2023-10-19 | Regents Of The University Of Michigan | Agents de dégradation d'ikzf2 et leurs utilisations |
WO2023205719A1 (fr) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Composés modulateurs de kras g12d |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024032689A1 (fr) * | 2022-08-10 | 2024-02-15 | 标新生物医药科技(上海)有限公司 | Composé à squelette glutarimide substitué par isoindoline et son utilisation |
WO2024059107A1 (fr) * | 2022-09-14 | 2024-03-21 | President And Fellows Of Harvard College | Composés de dégradation d'ikzf2 et de ck1-alpha et utilisations associées |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
US7196170B2 (en) | 1992-09-14 | 2007-03-27 | The General Hospital Corporation | Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
DE122007000079I2 (de) | 1996-07-24 | 2010-08-12 | Celgene Corp | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
AU2001291195A1 (en) | 2000-12-01 | 2002-06-11 | Parker Hughes Institute | Nucleotide and protein sequence of helios 3 and methods of use |
US7902179B2 (en) | 2001-04-26 | 2011-03-08 | Ajinomoto Co., Inc. | Heterocyclic compounds |
NZ531294A (en) | 2001-08-06 | 2005-11-25 | Childrens Medical Center | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7612096B2 (en) | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
US20070161696A1 (en) | 2004-04-23 | 2007-07-12 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
AU2005282728A1 (en) * | 2004-09-03 | 2006-03-16 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
JP4731867B2 (ja) | 2004-10-01 | 2011-07-27 | 国立大学法人三重大学 | Cd8陽性の細胞傷害性tリンパ球の誘導方法 |
BRPI0518793A2 (pt) | 2004-12-01 | 2008-12-09 | Celgene Corp | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica |
DE602005023646D1 (de) | 2004-12-10 | 2010-10-28 | Siemens Healthcare Diagnostics | Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung |
US20070128636A1 (en) | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
AU2006332680A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
MX2008012096A (es) | 2006-03-22 | 2008-12-17 | Vertex Pharma | Inhibidores de proteina cinasa c-met para el tratamiento de trastornos proliferativos. |
US20070269827A1 (en) | 2006-05-18 | 2007-11-22 | Oklahoma Medical Research Foundation | Predicting and Diagnosing Patients With Autoimmune Disease |
KR101342035B1 (ko) | 2006-06-20 | 2013-12-16 | 한국과학기술연구원 | 신장독성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 신장독성 및 부작용 유발 약물 검색 방법 |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
JP2009092508A (ja) | 2007-10-09 | 2009-04-30 | Norihiro Nishimoto | リウマチ治療剤の効果の予測方法 |
EP2227558A1 (fr) | 2007-11-30 | 2010-09-15 | GlaxoSmithKline Biologicals SA | Méthode de classement de patients atteints de cancer en répondants ou non-répondants à l'immunothérapie |
KR100957051B1 (ko) | 2007-12-28 | 2010-05-13 | 한국과학기술연구원 | 니트로푸란토인 처리에 따른, 폐독성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법 |
GB2456390A (en) | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
WO2009094592A2 (fr) | 2008-01-23 | 2009-07-30 | Perlegen Sciences, Inc. | Base génétique de la maladie d'alzheimer et diagnostic et traitement de cette dernière |
EP2227780A4 (fr) | 2008-03-19 | 2011-08-03 | Existence Genetics Llc | Analyse génétique |
US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
EP2177615A1 (fr) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Procédé pour une identification large du génome de séquences régulatrices de l'expression et utilisation de gènes et de molécules dérivées pour le diagnostic et le traitement de maladies métaboliques et/ou tumorales |
US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
RU2012104214A (ru) | 2009-08-05 | 2013-09-10 | Верситек Лимитед | Противовирусные соединения и способы их получения и применения |
US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
EP2494076B1 (fr) | 2009-10-26 | 2017-11-22 | Abbott Molecular Inc. | Détection d'anomalies chromosomiques associées au pronostic du cancer broncho-pulmonaire à grandes cellules |
US20130237454A1 (en) | 2010-05-12 | 2013-09-12 | Steven E. Schutzer | Diagnostic markers for neuropsychiatric disease |
US20120142701A1 (en) | 2010-05-28 | 2012-06-07 | The University Of Hong Kong | Compounds and methods for the treatment of proliferative diseases |
WO2011151941A1 (fr) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | Composition présentant une activité d'induction de la prolifération ou de l'accumulation de cellule t régulatrice |
WO2012021867A2 (fr) | 2010-08-13 | 2012-02-16 | The Johns Hopkins University | Carte exhaustive du méthylome au cours de la détermination des myéloïdes et lymphoïdes de progéniteurs hématopoïétiques |
JP2014502258A (ja) | 2010-10-22 | 2014-01-30 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 免疫反応を抑制するためにプログラムされた制御性t細胞の発見 |
CN104080454B (zh) | 2011-06-06 | 2017-02-15 | 爱荷华大学研究基金会 | 用于抑制肌萎缩的方法 |
WO2012175613A1 (fr) | 2011-06-21 | 2012-12-27 | Innate Pharma | Personnalisation de cellules nk à médiation par nkp46 |
EP2726879B1 (fr) | 2011-07-01 | 2022-10-19 | Beckman Coulter, Inc. | Lymphocytes t régulateurs et méthodes d'identification, d'obtention et d'utilisation de celles-ci en vue du traitement de troubles immunologiques |
CN103797120B (zh) | 2011-09-16 | 2017-04-12 | 上海长海医院 | 前列腺癌的生物学标志物、治疗靶点及其用途 |
EP2785828B1 (fr) | 2011-12-01 | 2020-04-08 | The University of Tokyo | Bactéries d'origine humaine qui induisent la prolifération ou l'accumulation de lymphocytes t régulateurs |
US9481866B2 (en) | 2011-12-16 | 2016-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations enriched for stable regulatory T-cells |
WO2013098797A2 (fr) | 2011-12-31 | 2013-07-04 | Kuriakose Moni Abraham | Tests de diagnostic pour prédiction de pronostic, récurrence, résistance ou sensibilité à une thérapie et un état métastatique dans un cancer |
WO2013131045A1 (fr) | 2012-03-02 | 2013-09-06 | The Regents Of The University Of California | Expansion de lymphocytes t régulateurs réagissant avec des alloantigènes |
GB201207297D0 (en) | 2012-04-26 | 2012-06-06 | Senzagen Ab | Analytical methods and arrays for use in the same |
GB201213571D0 (en) | 2012-07-31 | 2012-09-12 | Univ Leuven Kath | Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal |
EP2682750A1 (fr) | 2012-07-02 | 2014-01-08 | Sotio a.s. | DEL et procédé de fabrication de DEL |
EP3677310A1 (fr) | 2012-10-08 | 2020-07-08 | St. Jude Children's Research Hospital | Thérapies fondées sur la régulation de la stabilité et de la fonction des lymphocytes t régulateurs par l'intermédiaire d'un axe neuropiline-1:sémaphorine |
WO2014122467A1 (fr) | 2013-02-06 | 2014-08-14 | Loxbridge Research Llp | Systèmes et procédés pour la détection de maladie précoce et la surveillance de maladie en temps réel |
AU2014236285A1 (en) | 2013-03-14 | 2015-11-05 | Children's Medical Center Corporation | Compositions and methods for reprogramming hematopoietic stem cell lineages |
EP2971164B1 (fr) | 2013-03-15 | 2023-07-26 | Veracyte, Inc. | Procédés et compositions pour classification d'échantillons |
WO2014200952A2 (fr) | 2013-06-10 | 2014-12-18 | Suregene, Llc | Marqueurs génétiques de la réponse aux antipsychotiques |
US20150167085A1 (en) | 2013-09-09 | 2015-06-18 | Daniel R. Salomon | Methods and Systems for Analysis of Organ Transplantation |
WO2015050875A1 (fr) | 2013-10-01 | 2015-04-09 | The Regents Of The University Of California | Classificateur pour endométriose |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
WO2015109212A1 (fr) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anticorps anti-il-2 et compositions et utilisations de ceux-ci |
WO2015107196A1 (fr) | 2014-01-20 | 2015-07-23 | Institut Curie | Utilisation de thalidomide ou d'analogues de celui-ci pour la prévention de troubles neurologiques induits par une irradiation du cerveau |
KR20240038809A (ko) * | 2014-04-14 | 2024-03-25 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
AU2015357573B2 (en) | 2014-12-05 | 2022-04-07 | Foundation Medicine, Inc. | Multigene analysis of tumor samples |
EP3034620A1 (fr) | 2014-12-17 | 2016-06-22 | Diaxonhit | Compositions et procédés permettant de diagnostiquer un cancer de la thyroïde |
WO2016103269A1 (fr) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations de cellules progénitrices neuronales et leurs procédés de production et d'utilisation |
CN107257793A (zh) | 2015-01-20 | 2017-10-17 | 梅里亚股份有限公司 | 抗蠕虫化合物、组合物及其使用方法 |
EP3050570A1 (fr) | 2015-01-31 | 2016-08-03 | Neurovision Pharma GmbH | Composition pharmaceutique comprenant une combinaison de G-CSF avec GM-CSF |
WO2016140974A1 (fr) | 2015-03-01 | 2016-09-09 | Novena Therapeutics Inc. | Procédé de mesure de la réponse d'une tumeur à un traitement oncologique initial |
CN107787320B (zh) | 2015-05-22 | 2020-12-04 | 拜欧赛里克斯公司 | 靶向蛋白质的化合物、其组合物、方法和用途 |
EP3304076A4 (fr) | 2015-06-02 | 2018-12-19 | Celgene Corporation | Méthodes permettant de déterminer l'efficacité de médicaments dans le traitement du cancer à l'aide des rapports de protéines associées au céréblon |
CA2988119A1 (fr) | 2015-06-03 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Procedes pour induire la conversion de cellules t regulatrices dans des cellules t effectrices pour l'immunotherapie cancereuse |
JP2018519295A (ja) | 2015-06-22 | 2018-07-19 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 粘膜固有層調節性t細胞の誘導 |
WO2017042337A1 (fr) | 2015-09-09 | 2017-03-16 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmhotz-Gemeinschaft | Acides gras à chaîne courte destinés à être utilisés pour le traitement d'une maladie cardiovasculaire |
US20180250369A1 (en) | 2015-09-11 | 2018-09-06 | Ventria Bioscience, Inc. | Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases |
WO2017058881A1 (fr) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Utilisation de la pentoxifylline sous thérapies de blocage des points de contrôle immunitaires pour le traitement du mélanome |
AU2016330967B2 (en) | 2015-09-30 | 2021-03-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thalidomide analogs and methods of use |
WO2017075465A1 (fr) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de gata3 |
WO2017075451A1 (fr) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de pou2af1 |
WO2017075478A2 (fr) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions et méthodes d'évaluation et de modulation des réponses immunitaires à l'aide de signatures génétiques de cellules immunitaires |
EP3384013A4 (fr) | 2015-12-04 | 2019-07-10 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Lymphocytes t spécifiques d'un antigène pour induire une tolérance immunitaire |
US20190119642A1 (en) | 2016-03-15 | 2019-04-25 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
JP7001614B2 (ja) | 2016-04-06 | 2022-02-03 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | リガンド依存性の標的タンパク質分解のための単官能性中間体 |
WO2017191274A2 (fr) | 2016-05-04 | 2017-11-09 | Curevac Ag | Arn codant pour une protéine thérapeutique |
WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
EP3455219A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles |
RS64208B1 (sr) | 2016-10-11 | 2023-06-30 | Arvinas Operations Inc | Jedinjenja i metode za ciljanu degradaciju androgenog receptora |
WO2018119448A1 (fr) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Composés et methodes pour la dégradation ciblée de polypeptides de fibrosarcome rapidement accéléré |
EP3559006A4 (fr) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | Composés et procédés pour la dégradation ciblée de polypeptides de kinase du foie f tal |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
JP7266526B6 (ja) | 2017-01-26 | 2024-02-15 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体タンパク質分解性の調節因子およびその関連方法 |
CN106932576A (zh) | 2017-03-22 | 2017-07-07 | 山东大学深圳研究院 | 一种人调节性t细胞的免疫抑制功能的检测方法 |
TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
-
2018
- 2018-08-21 TW TW107129068A patent/TWI793151B/zh active
- 2018-08-22 AR ARP180102390 patent/AR112529A1/es unknown
- 2018-08-22 US US16/108,713 patent/US10414755B2/en active Active
- 2018-08-22 UY UY0001037854A patent/UY37854A/es not_active Application Discontinuation
- 2018-08-23 ES ES18772885T patent/ES2940448T3/es active Active
- 2018-08-23 EP EP18772885.2A patent/EP3672949B9/fr active Active
- 2018-08-23 JP JP2020510565A patent/JP7386787B2/ja active Active
- 2018-08-23 MX MX2020002060A patent/MX2020002060A/es unknown
- 2018-08-23 JO JOP/2020/0042A patent/JOP20200042A1/ar unknown
- 2018-08-23 CU CU2020000014A patent/CU20200014A7/es unknown
- 2018-08-23 EP EP22213789.5A patent/EP4183782A1/fr not_active Withdrawn
- 2018-08-23 WO PCT/IB2018/056400 patent/WO2019038717A1/fr unknown
- 2018-08-23 CN CN201880053653.2A patent/CN111051298B/zh active Active
- 2018-08-23 KR KR1020207007884A patent/KR20200044038A/ko not_active Application Discontinuation
- 2018-08-23 MA MA49952A patent/MA49952B1/fr unknown
- 2018-08-23 CR CR20200081A patent/CR20200081A/es unknown
- 2018-08-23 PL PL18772885.2T patent/PL3672949T3/pl unknown
- 2018-08-23 PT PT187728852T patent/PT3672949T/pt unknown
- 2018-08-23 EA EA202090553A patent/EA202090553A1/ru unknown
- 2018-08-23 DK DK18772885.2T patent/DK3672949T5/da active
- 2018-08-23 LT LTEPPCT/IB2018/056400T patent/LT3672949T/lt unknown
- 2018-08-23 BR BR112020003373-1A patent/BR112020003373B1/pt active IP Right Grant
- 2018-08-23 RS RS20230203A patent/RS64058B9/sr unknown
- 2018-08-23 SG SG11202000490PA patent/SG11202000490PA/en unknown
- 2018-08-23 AU AU2018319577A patent/AU2018319577B2/en active Active
- 2018-08-23 HR HRP20230244TT patent/HRP20230244T1/hr unknown
- 2018-08-23 CA CA3072694A patent/CA3072694A1/fr active Pending
- 2018-08-23 FI FIEP18772885.2T patent/FI3672949T3/fi active
- 2018-08-23 SI SI201830871T patent/SI3672949T1/sl unknown
- 2018-08-23 HU HUE18772885A patent/HUE061895T2/hu unknown
-
2019
- 2019-08-05 US US16/532,106 patent/US10640489B2/en active Active
- 2019-08-05 US US16/532,118 patent/US10647701B2/en active Active
-
2020
- 2020-01-13 ZA ZA2020/00208A patent/ZA202000208B/en unknown
- 2020-01-17 PH PH12020500125A patent/PH12020500125A1/en unknown
- 2020-02-18 IL IL272748A patent/IL272748B2/en unknown
- 2020-02-20 CO CONC2020/0001860A patent/CO2020001860A2/es unknown
- 2020-02-20 EC ECSENADI202013248A patent/ECSP20013248A/es unknown
- 2020-02-20 SA SA520411325A patent/SA520411325B1/ar unknown
- 2020-02-20 CL CL2020000427A patent/CL2020000427A1/es unknown
- 2020-02-20 DO DO2020000037A patent/DOP2020000037A/es unknown
- 2020-03-31 US US16/835,938 patent/US11053218B2/en active Active
- 2020-11-26 AU AU2020277231A patent/AU2020277231A1/en not_active Abandoned
-
2021
- 2021-06-09 US US17/343,016 patent/US20210309638A1/en not_active Abandoned
-
2022
- 2022-09-13 AU AU2022231670A patent/AU2022231670A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49952B1 (fr) | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations | |
MA47368B1 (fr) | N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA40893B1 (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA45020B1 (fr) | Dérivés sulfonamides aromatiques | |
TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA45888A1 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
MA30433B1 (fr) | Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires | |
MA47469B1 (fr) | Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer | |
MA54386B1 (fr) | Modulateurs de trex1 | |
MA43468B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA39688B1 (fr) | Composés hétéroaryle pour le traitement de maladies ophtalmiques | |
MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
MA50069B1 (fr) | Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique | |
MA44965B1 (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
MA34746B1 (fr) | Dérivés de diphénylamine : utilisations, procédés de synthèse et compositions pharmaceutiques | |
MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer |